Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors
Why invest in PAR?
Paradigm Biopharmaceuticals: THE INVESTMENT CASE

Paradigm Biopharmaceuticals: Access latest PPT from Proactive's CEO Sessions

Paul Rennie talked timeline to clinical trial results with investors.
Paradigm Biopharmaceuticals: Access latest PPT from Proactive's CEO Sessions
INVESTMENT OVERVIEW: PAR The Big Picture
Paul Rennie, chief executive officer, Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals (ASX:PAR) chief executive officer, Paul Rennie, joined Proactive's CEO Sessions in Melbourne on Tuesday 16th May and Sydney on Wednesday 17th May.

Paradigm has results from its Phase 2 hay fever trial pending in six weeks.

ACCESS THE FULL PRESENTATION HERE



Register here to be notified of future PAR Company articles
View full PAR profile View Profile

Paradigm Biopharmaceuticals Timeline

Related Articles

Knee.jpg
February 14 2017
It has unveiled plans to raise as much as £12mln, which should transform the business.
brokerreport.jpg
January 25 2017
Analyst Vadim Alexandre, of the company’s broker Northland Capital, said Wednesday’s update provided “better visibility” on the trial timetable.
Vaxil at the vanguard of immuno-oncology
January 06 2017
The company is developing ImMucin, which targets MUC-1, a unique cancer antigen with high specificity to malignant cells, and results in a potent stimulation effect on T and B cells.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use